Welcome to our dedicated page for Bausch + Lomb Corporation news (Ticker: BLCO), a resource for investors and traders seeking the latest updates and insights on Bausch + Lomb Corporation stock.
Bausch + Lomb Corporation (BLCO) delivers essential vision care solutions through its innovative contact lenses, surgical technologies, and ophthalmic pharmaceuticals. This news hub provides investors and industry professionals with timely updates on the company’s latest developments across all business segments.
Track official press releases, financial announcements, and strategic initiatives in one centralized location. Our curated collection includes updates on product approvals, earnings results, research breakthroughs, and partnerships that shape the future of eye health innovation.
Discover how BLCO’s three core segments – Vision Care, Surgical, and Ophthalmic Pharmaceuticals – continue advancing ocular treatment standards worldwide. The company’s commitment to clinical excellence and regulatory compliance remains central to all updates shared here.
Bookmark this page for direct access to verified information about Bausch + Lomb’s market activities. Check regularly for new developments impacting the vision care industry and BLCO’s position as a leader in medical eye solutions.
Outcome Capital announces the successful acquisition of Elios Vision by Bausch + Lomb (NYSE/TSX: BLCO). Elios Vision, a developer of minimally invasive glaucoma surgery (MIGS) using excimer laser technology, has created the ELIOS™ procedure, an implant-free treatment designed to reduce intraocular pressure in glaucoma patients while minimizing risks associated with traditional surgeries.
The technology is currently CE-marked and available in the European Union, with FDA approval being sought this year. The procedure can be performed standalone or alongside cataract surgery, offering broader adoption potential due to its relative simplicity compared to implant-based MIGS. The acquisition strengthens Bausch + Lomb's position in the $2.5 billion glaucoma treatment market, addressing a condition that affects over 76 million people globally.
Bausch + Lomb (NYSE/TSX: BLCO) and Glaucoma Research Foundation (GRF) are launching their second annual 'Faces of Glaucoma' campaign during Glaucoma Awareness Month in January. The initiative aims to raise awareness about glaucoma, the second leading cause of blindness worldwide, by sharing diverse patient stories and educational resources.
The campaign highlights that approximately half of people with glaucoma are unaware they have the condition. As part of the initiative, Bausch + Lomb will match donations up to $20,000 for the fourth consecutive year to support GRF's research toward finding a cure.
The campaign emphasizes that while glaucoma is often associated with older individuals, it can affect anyone regardless of race, age, or gender. Early intervention, including prescription eye drops, can help slow the disease's progression, though there is currently no cure. Detection requires yearly comprehensive dilated eye exams by eye care professionals.
Bausch + Lomb (NYSE/TSX: BLCO) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's leadership team, including Chairman and CEO Brent Saunders, CFO Sam Eldessouky, and Chief Medical Officer and Head of R&D Yehia Hashad, M.D., will deliver a company presentation on Monday, January 13, 2025, at 11:15 a.m. PT (2:15 p.m. ET).
The global eye health company will provide a live webcast of the event, with an audio archive available afterward on their Investor Relations page at http://ir.bausch.com/investors/events-presentations.
Bausch + Lomb (NYSE/TSX: BLCO) has confirmed it is exploring a potential sale as one of several options to achieve complete separation from Bausch Health Companies Inc. The company's board of directors has authorized management and advisors to explore this possibility, though no transaction is guaranteed. This statement was issued in response to a request from the Canadian Investment Regulatory Organization (CIRO) due to stock volatility concerns related to market rumors. The company stated it will not provide additional details until further disclosure becomes appropriate or necessary.
Bausch + Lomb (NYSE/TSX: BLCO) has acquired Elios Vision, Inc., developer of the ELIOS™ procedure, the first clinically validated, minimally invasive glaucoma surgery (MIGS) using an excimer laser. The acquisition strengthens BLCO's glaucoma portfolio by introducing a differentiated treatment approach that can be performed alongside cataract surgery.
The ELIOS system offers a tissue-friendly, non-thermal laser-based procedure for glaucoma, which is expected to see a 47% prevalence increase from 2020 to 2040. The technology is currently CE marked and available in the European Union, with FDA approval pending. Over 19% of cataract surgery patients also have glaucoma or ocular hypertension, presenting an opportunity for concurrent treatment.
Bausch + Lomb (NYSE/TSX: BLCO) announced significant achievements in its recycling initiatives, with its ONE by ONE Recycling and Biotrue Eye Care Recycling programs collecting over 94 million units (569,743 pounds) of used contact lenses, eye care, and lens care materials in the United States. This recycling effort addresses a important environmental concern, as an estimated 6-10 metric tons of contact lenses end up in wastewater annually in the US. The programs, operated in collaboration with TerraCycle, help prevent these materials from ending up in landfills or waterways, where they could potentially impact aquatic environments and the human food supply.
Bausch + Lomb (NYSE/TSX: BLCO) reported strong Q3 2024 results with total revenue of $1.196 billion, up 19% year-over-year. The company achieved growth across all segments: Vision Care revenue reached $684 million (+6%), Surgical revenue hit $206 million (+11%), and Pharmaceuticals revenue grew to $306 million (+76%). GAAP Net Income was $4 million, compared to a net loss of $84 million in Q3 2023. Adjusted EBITDA increased to $212 million. Based on strong performance, the company raised its full-year 2024 revenue guidance to $4.725-$4.825 billion.
Bausch + Lomb (NYSE/TSX: BLCO) has received FDA approval for the enVista® Envy™ full range of vision intraocular lens (IOL). This new IOL offers a continuous range of vision with excellent dysphotopsia tolerance on the enVista IOL platform.
Key findings from clinical trials include:
- 86% of patients reported little to no bothersomeness for dysphotopsia
- 94% of patients reported little to no difficulty viewing close objects
- 93% were completely to moderately satisfied with their vision post-surgery
The enVista Envy IOL features ActivSync Optic intelligent energy distribution for optimal vision in various lighting conditions. It also allows surgeons to treat a wider range of astigmatic patients with more accuracy. The product will be available on a basis in the coming weeks and more broadly in 2025.
Bausch + Lomb (NYSE/TSX: BLCO), a leading global eye health company, has announced it will release its third-quarter 2024 financial results on Wednesday, October 30, 2024. The company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update.
Interested parties can access the webcast through the provided link or join via phone using the specified dial-in numbers. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the call. A replay of the call will be available until November 13, 2024, using the provided replay dial-in numbers and passcode.
Bausch + Lomb (NYSE/TSX: BLCO) has launched Opal, a digital e-commerce marketplace in the United States. This platform is designed to streamline the ordering process for Bausch + Lomb contact lenses and select over-the-counter products, aiming to maximize efficiencies for eye care practices and enhance patient experience.
Key features of Opal include:
- Complimentary offering for eye care professionals
- Order tracking and history
- Appointment and prescription reminders
- Free shipping to patients' homes or practices
- Integration with Bausch + Lomb Horizon Rewards loyalty program
The platform simplifies administrative tasks, inventory management, and cost comparisons, potentially freeing up resources and staff time for eye care practices while supporting business growth.
